Business
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nNon-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options.\n\n\n\nPublication highlights in vitro and in vivo results supporting LP-284’s development for mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs.\n\n\n\nLantern is anticipating filing the IND application with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in NHL, including MCL, during the second half of 2023.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (\"AI\") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284’s in vitro and in vivo antitumor potency for multiple non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). The journal article titled “LP-284 Targets Non-Hodgkin's Lymphoma and DNA Damage Repair Deficiency” further supports LP-284’s development for NHL and advancement towards a first-in-human Phase 1 trial, which is anticipated for the second half of 2023.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230626167658/en/Lantern publishes new research in Oncotarget demonstrating LP-284’s antitumor potential for multiple non-Hodgkin’s lymphomas (Graphic: Business Wire)\nNon-Hodgkin’s lymphomas (NHL) remain one of the leading causes of cancer deaths globally and have an estimated 500,000 new cases globally, with NHL being the leading hematological malignancy in the US. Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment. In aggressive subtypes of NHL, like MCL, nearly all patients relapse from standard-of-care (SOC) therapies.\n\n\n“Given the efficacy of drug candidate LP-284 in preclinical studies and the mechanism of synthetic lethality where LP-284 seems to prefer blood cancers with deficiencies in the DNA repair pathways, we believe this drug candidate can be a powerful t...